Sintilimab, produced by Innovbio , represents a crucial advance in cancer management. This monoclonal therapy is a PD-1 blocker , meant to unlock the body's defense against tumors . Medical studies have https://www.targetmol.com/compound/sintilimab_%28anti-pd-1%29